{'fraction_non_alphanumeric': 0.023722627737226276, 'fraction_numerical': 0.010948905109489052, 'mean_word_length': 5.949367088607595, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics of C1‐inhibitor protein in patients with acute myocardial infarction

C1‐inhibitor protein (C1‐INH) purified from pooled human plasma is used for the treatment of patients with hereditary angioedema. Recently, the beneficial effects of high‐dose C1‐INH treatment on myocardial ischemia or reperfusion injury have been reported in various animal models and in humans. We investigated the pharmacokinetic behavior of C1‐INH in patients with acute myocardial infarction to calculate the amount of C1‐INH required for optimal efficacy.